Vivani Medical (VANI)
NASDAQ:VANI
Want to see VANI full AI Analyst Report?
Top Page
Vivani Medical
(NASDAQ:VANI)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▲(17.19% Upside)
Action:ReiteratedDate:04/18/26
The score is held down primarily by weak financial performance (pre-revenue, large recurring losses, and significant cash burn with rising leverage). Technicals are a partial offset with price above key moving averages and a positive MACD, but overbought signals (high RSI/Stoch) add pullback risk. Valuation remains challenged due to the negative P/E and lack of dividend support.
Positive Factors
Long-acting implant platform
A proprietary long-acting implant platform is a durable competitive asset: sustained delivery addresses adherence issues in chronic care and can differentiate products versus frequent-dosing alternatives. If clinical programs progress, the platform supports multi-indication leverage and longer-term commercial stickiness.
Negative Factors
Pre-revenue status
Being pre-revenue is a fundamental constraint: no product sales mean operations depend entirely on external financing. This elevates execution and financing risk over the medium term, as the firm must demonstrate clinical progress before realizing sustainable cash inflows or commercial validation.
Read all positive and negative factors
Positive Factors
Negative Factors
Long-acting implant platform
A proprietary long-acting implant platform is a durable competitive asset: sustained delivery addresses adherence issues in chronic care and can differentiate products versus frequent-dosing alternatives. If clinical programs progress, the platform supports multi-indication leverage and longer-term commercial stickiness.
Read all positive factors
Vivani Medical (VANI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$111.74M
Dividend YieldN/A
Average Volume (3M)216.92K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue GrowthN/A
EPS Growth0.28%
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.09
Shares Outstanding84,647,804
10 Day Avg. Volume237,036
30 Day Avg. Volume216,922
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-366.39
Enterprise Value/Ebitda-2.98
Forecast
1Y Price Target
$3.75Price Target Upside192.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Vivani Medical Business Overview & Revenue Model
Company Description
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and...
How the Company Makes Money
null...
Vivani Medical Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -424.00K | 0.00 | -357.00K | 0.00 | 0.00 |
| EBITDA | -27.13M | -24.28M | -25.30M | -19.16M | -12.98M |
| Net Income | -26.61M | -23.49M | -25.65M | -13.89M | -12.77M |
Balance Sheet | |||||
| Total Assets | 39.39M | 41.56M | 45.80M | 51.13M | 5.45M |
| Cash, Cash Equivalents and Short-Term Investments | 16.23M | 18.35M | 20.65M | 45.08M | 2.18M |
| Total Debt | 18.86M | 19.31M | 20.70M | 955.00K | 1.81M |
| Total Liabilities | 23.66M | 23.95M | 25.04M | 6.82M | 2.99M |
| Stockholders Equity | 15.73M | 17.61M | 20.76M | 44.31M | 2.46M |
Cash Flow | |||||
| Free Cash Flow | -25.49M | -21.34M | -24.59M | -19.13M | -11.52M |
| Operating Cash Flow | -24.32M | -20.79M | -23.70M | -18.79M | -10.95M |
| Investing Cash Flow | -1.17M | -556.00K | -887.00K | -338.00K | -572.00K |
| Financing Cash Flow | 23.27M | 19.05M | 133.00K | 63.39M | 11.62M |
Vivani Medical Technical Analysis
Positive
1.28
Price Trends
1.17
Positive
1.26
Positive
1.34
Positive
Market Momentum
0.01
Negative
68.81
Neutral
93.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VANI, the sentiment is Positive. The current price of 1.28 is above the 20-day moving average (MA) of 1.10, above the 50-day MA of 1.17, and below the 200-day MA of 1.34, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 68.81 is Neutral, neither overbought nor oversold. The STOCH value of 93.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VANI.
Vivani Medical Risk Analysis
Vivani Medical disclosed 65 risk factors in its most recent earnings report. Vivani Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vivani Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $118.93M | 14.16 | 4.34% | ― | 4.39% | -2.08% | |
60 Neutral | $76.30M | 22.00 | 10.27% | ― | 14.21% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $124.07M | -4.20 | -111.74% | ― | ― | ― | |
48 Neutral | $111.74M | -2.88 | -317.03% | ― | ― | 0.28% | |
47 Neutral | $18.55M | -2.58 | -221.04% | ― | 2.67% | 20.58% | |
45 Neutral | $53.46M | -2.68 | -116.22% | ― | 28.11% | -2.63% |
* Healthcare Sector Average
VANI
Vivani Medical
1.32
0.29
28.16%
EDAP
EDAP TMS
3.31
1.19
56.13%
FONR
Fonar
18.94
6.39
50.92%
NSPR
InspireMD
1.14
-1.40
-55.12%
XTNT
Xtant Medical Holdings
0.54
0.04
7.09%
ICCM
Icecure Medical
0.27
-0.97
-78.23%
Vivani Medical Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Vivani Medical Announces Equity Offerings to Fund Pipeline
Positive
Jan 27, 2026
On January 25, 2026, Vivani Medical, Inc. priced a best-efforts registered direct offering of 1,689,200 common shares at $1.48 per share and a concurrent private placement of 1,351,351 common shares at the same price to an entity affiliated with b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.